TY - CHAP
T1 - Muscle Cell Transplants
AU - Lavasani, Mitra
AU - Pollett, Jonathan
AU - Huard, Johnny
N1 - Funding Information:
We wish to thank Ryan Sauder for his excellent editorial assistance with the manuscript, Dr. Burhan Gharaibeh for his assistance with the artwork in Figure 16.2 , and Ken Urish for providing the EP image shown in Figure 16.3 . This work was supported in part by grants to Dr. Huard from the National Institutes of Health (R01 AR049684, R01 DE13420, R01 DK55387, R01 AR049398), the Department of Defense, the Muscular Dystrophy Association (USA), the Pittsburgh Tissue Engineering Initiative (PTEI), the William F. and Jean W. Donaldson Chair at Children's Hospital of Pittsburgh, and the Henry J. Mankin Endowed Chair at the University of Pittsburgh.
PY - 2007
Y1 - 2007
N2 - This chapter provides an example of a significant discovery that resulted from what researchers initially perceived as a negative clinical finding, which they then explored further in the laboratory. The main stumbling block impeding many therapeutic approaches, including the treatment of Duchenne muscular dystrophy (DMD), is the difficulty associated with delivering therapeutic agents at levels sufficient to provide benefit. Stem cells offer many exciting possibilities for the development of novel treatments to alleviate numerous devastating diseases. In particular, muscle-derived stem cells (MDSC)-based therapy holds vast therapeutic potential due to MDSCs' survival ability, unique immuneprivileged behavior, long-term proliferative potential, and pluripotency. Such characteristics strongly indicate that these cells could be useful for the treatment of DMD and other conditions of the musculoskeletal system. These cells provide a good example of what can happen when clinicians and researchers work hand-in-hand to appropriately interpret the outcome of clinical applications. Much work remains to be done before applications based on these cells progress from bench back to the bedside, but the preliminary data reviewed here strongly suggest that the future application of these techniques is promising.
AB - This chapter provides an example of a significant discovery that resulted from what researchers initially perceived as a negative clinical finding, which they then explored further in the laboratory. The main stumbling block impeding many therapeutic approaches, including the treatment of Duchenne muscular dystrophy (DMD), is the difficulty associated with delivering therapeutic agents at levels sufficient to provide benefit. Stem cells offer many exciting possibilities for the development of novel treatments to alleviate numerous devastating diseases. In particular, muscle-derived stem cells (MDSC)-based therapy holds vast therapeutic potential due to MDSCs' survival ability, unique immuneprivileged behavior, long-term proliferative potential, and pluripotency. Such characteristics strongly indicate that these cells could be useful for the treatment of DMD and other conditions of the musculoskeletal system. These cells provide a good example of what can happen when clinicians and researchers work hand-in-hand to appropriately interpret the outcome of clinical applications. Much work remains to be done before applications based on these cells progress from bench back to the bedside, but the preliminary data reviewed here strongly suggest that the future application of these techniques is promising.
UR - http://www.scopus.com/inward/record.url?scp=84882513483&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84882513483&partnerID=8YFLogxK
U2 - 10.1016/B978-012369415-7/50017-X
DO - 10.1016/B978-012369415-7/50017-X
M3 - Chapter
AN - SCOPUS:84882513483
SN - 9780123694157
SP - 289
EP - 302
BT - Cellular Transplantation
PB - Elsevier Inc
ER -